EMA Application withdrawn: HemAryo (eptacog alfa (activated)) — UGA Biopharma

View source ↗

Summary

EMA withdrawn the application for HemAryo (eptacog alfa activated) by UGA Biopharma for hemophilia A, hemophilia B, and factor VII deficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Factor Vii Deficiency
• Hemophilia

Drugs mentioned

• HemAryo (eptacog alfa (activated))

Snippet

Status: Application withdrawn. Therapeutic area: Hemophilia A;Hemophilia B;Factor VII Deficiency. MAH: UGA Biopharma. Decision date: 19/05/2022